HUP9902097A3 - Method for treating glaucoma - Google Patents

Method for treating glaucoma

Info

Publication number
HUP9902097A3
HUP9902097A3 HU9902097A HUP9902097A HUP9902097A3 HU P9902097 A3 HUP9902097 A3 HU P9902097A3 HU 9902097 A HU9902097 A HU 9902097A HU P9902097 A HUP9902097 A HU P9902097A HU P9902097 A3 HUP9902097 A3 HU P9902097A3
Authority
HU
Hungary
Prior art keywords
treating glaucoma
glaucoma
treating
Prior art date
Application number
HU9902097A
Other languages
Hungarian (hu)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HU9902097D0 publication Critical patent/HU9902097D0/en
Publication of HUP9902097A2 publication Critical patent/HUP9902097A2/en
Publication of HUP9902097A3 publication Critical patent/HUP9902097A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HU9902097A 1998-06-23 1999-06-22 Method for treating glaucoma HUP9902097A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9038698P 1998-06-23 1998-06-23

Publications (3)

Publication Number Publication Date
HU9902097D0 HU9902097D0 (en) 1999-08-30
HUP9902097A2 HUP9902097A2 (en) 2000-05-28
HUP9902097A3 true HUP9902097A3 (en) 2003-02-28

Family

ID=22222561

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902097A HUP9902097A3 (en) 1998-06-23 1999-06-22 Method for treating glaucoma

Country Status (11)

Country Link
US (1) US6344485B1 (en)
EP (1) EP1000619A3 (en)
JP (1) JP2000053566A (en)
KR (1) KR20000006372A (en)
AU (1) AU745544B2 (en)
CA (1) CA2275827C (en)
HU (1) HUP9902097A3 (en)
IL (1) IL130531A (en)
MY (1) MY120578A (en)
NZ (1) NZ336394A (en)
ZA (1) ZA994105B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA59384C2 (en) * 1996-12-20 2003-09-15 Пфайзер, Інк. Preventing bone mass loss and recovery thereof by means of prostaglandin agonists
DE10209645A1 (en) * 2002-03-05 2003-09-18 Bayer Cropscience Ag Substituted aryl ketones
AU2003233729B2 (en) * 2002-06-06 2007-10-04 Merck Frosst Canada Ltd 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma
US20020168424A1 (en) * 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7314890B2 (en) * 2005-08-22 2008-01-01 Allergan, Inc. Sulfonamides
JP4583500B2 (en) 2006-07-28 2010-11-17 ファイザー・プロダクツ・インク EP2 agonist
CN101495452B (en) * 2006-07-28 2012-04-25 辉瑞产品公司 EP2 agonists
WO2009070910A2 (en) 2007-12-07 2009-06-11 Givaudan Sa Carboxamide derivatieves having cooling properties
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
EP3256112A1 (en) * 2015-02-13 2017-12-20 Canbex Therapeutics Limited Compounds for treating disorders associated with bk channel modulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5462968A (en) * 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
IL130333A0 (en) * 1996-12-20 2000-06-01 Pfizer Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists
UA59384C2 (en) * 1996-12-20 2003-09-15 Пфайзер, Інк. Preventing bone mass loss and recovery thereof by means of prostaglandin agonists
UA67754C2 (en) * 1997-10-10 2004-07-15 Пфайзер, Інк. Prostaglandin agonists and use thereof for the treatment of bone disorders

Also Published As

Publication number Publication date
EP1000619A2 (en) 2000-05-17
HUP9902097A2 (en) 2000-05-28
AU3580499A (en) 2000-01-06
AU745544B2 (en) 2002-03-21
EP1000619A3 (en) 2002-07-24
IL130531A0 (en) 2000-06-01
JP2000053566A (en) 2000-02-22
KR20000006372A (en) 2000-01-25
CA2275827C (en) 2003-08-05
US6344485B1 (en) 2002-02-05
MY120578A (en) 2005-11-30
NZ336394A (en) 2000-11-24
IL130531A (en) 2004-12-15
HU9902097D0 (en) 1999-08-30
CA2275827A1 (en) 1999-12-23
ZA994105B (en) 2000-12-22

Similar Documents

Publication Publication Date Title
AU2593900A (en) Composition and method for treating glaucoma
EP1414464A4 (en) Method for treating glaucoma v
HK1010220A1 (en) Method for surface treatment.
HU9602482D0 (en) Method for treating 5ht2b receptor related conditions
AU2777999A (en) Method for treating plants
ZA952022B (en) Method for treating 5HT2B receptor related conditions
GB9809414D0 (en) Method
HK1039449A1 (en) Methods for treating multiple sclerosis
EP1267903A4 (en) Methods for treating glaucoma
HUP9902097A3 (en) Method for treating glaucoma
AU5733099A (en) Method for treating ocular neovascular diseases
EP1009403A4 (en) Method for treating schizophrenia
EG23945A (en) Method for treating COPD
GB9810722D0 (en) Method
EP1359910A4 (en) Method for treating glaucoma ii b
GB9802475D0 (en) Method
EP1043994A4 (en) Method for treating multiple sclerosis
AU6896098A (en) Method for treating schizophrenia
GB9809780D0 (en) Method
GB9809782D0 (en) Method
AU2443599A (en) Method for treating neoplasms
GB9804355D0 (en) Method
SG77660A1 (en) Method for reducing alpha-aminoketone
HU0500389D0 (en) Method for treating dyskinesias
IL121222A0 (en) Method for treating 5HT2b receptor related conditions